Related Experiment Video
Updated: Jun 24, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 24, 2014
Characterizing Japanese older adults without dementia by amyloid PET status: A comparative study of amyloid-positive
Saki Nakashima1, Kenichiro Sato2,3, Yoshiki Niimi3
1Department of Neurology Graduate School of Medicine The University of Tokyo Bunkyo-ku Tokyo Japan.
Introduction:
This study aimed to identify demographic and cognitive differences based on amyloid status in older Japanese adults without dementia, addressing the lack of data in East Asian populations for early Alzheimer's disease (AD) detection.
Methods:
Analyzed baseline data from 630 participants from the Japanese Trial-Ready Cohort (J-TRC) study, all with a Clinical Dementia Rating-Global Score (CDR-GS) of 0 or 0.5. Amyloid status (Aβ+ or Aβ-) was determined by amyloid positron emission tomography (PET) scans.
Results:
Among participants, 24.8% were Aβ+. In the cognitively unimpaired (CDR-GS 0) group, Aβ+ individuals reported slightly greater self-perceived cognitive concerns (Cognitive Function Instrument [CFI-self]). For those with mild impairment (CDR-GS 0.5), Aβ+ status was associated with worse clinical scores, greater cognitive complaints, more depressive symptoms, and poorer memory and global cognition.
Discussion:
These findings align with major Western studies, emphasizing that CFI-self is a valuable tool for identifying early AD pathology across diverse populations.
Highlights:
Comparing characteristics by amyloid status in Japanese non-demented older adults.Positron emission tomography-positive (PET+) scans in cognitively unimpaired individuals were associated with Cognitive Function Instrument-negative (CFI-) participants.PET+ in mild cognitive impairment (MCI) was linked to functional, cognitive, and affective decline.CFI- participants will aid early Alzheimer's pathology detection in diverse groups.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Alzheimer Disease l: Introduction
Alzheimer Disease ll: Pathophysiology

